Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (351)

91

Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy

enthalten in: Ophthalmology | 2015

von Kwon, S. | Shin, J. | Kim, I. | +1

92

Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials

enthalten in: Ophthalmology | 2015

von Ciulla, T. | Cuilla, T. | Ying, G. | +6

93

Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration

enthalten in: Ophthalmology | 2015

von Arnold, J. | Campain, A. | Barthelmes, D. | +7

94

Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial

enthalten in: Ophthalmology | 2015

von Campochiaro, P. | Hafiz, G. | Mir, T. | +12

95

The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema

enthalten in: Ophthalmology | 2015

von Brown, G. | Brown, M. | Turpcu, A. | +1

96

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab

enthalten in: Ophthalmology | 2015

von Sophie, R. | Lu, N. | Campochiaro, P.

97

The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema

enthalten in: Ophthalmology | 2015

von Ishibashi, T. | Li, X. | Koh, A. | +9

98

Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials

enthalten in: Ophthalmology | 2015

von Bansal, A. | Khurana, R. | Wieland, M. | +3

99

Author reply: To PMID 25001158

enthalten in: Ophthalmology | 2015

von Lepore, D. | Quinn, G.

100

VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration

enthalten in: Ophthalmology | 2015

von Hagstrom, S. | Ying, G. | Maguire, M. | +4